[HTML][HTML] A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable
Background Recent evidence suggested a potential correlation between overweight and the
efficacy of immune checkpoint inhibitors (ICIs) in cancer patients. Patients and methods We …
efficacy of immune checkpoint inhibitors (ICIs) in cancer patients. Patients and methods We …
[HTML][HTML] Early prediction of response to tyrosine kinase inhibitors by quantification of EGFR mutations in plasma of NSCLC patients
A Marchetti, JF Palma, L Felicioni, TM De Pas… - Journal of Thoracic …, 2015 - Elsevier
Introduction The potential to accurately quantify epidermal growth factor receptor (EGFR)
mutations in plasma from non–small-cell lung cancer patients would enable more rapid and …
mutations in plasma from non–small-cell lung cancer patients would enable more rapid and …
Clinical outcomes of patients with advanced cancer and pre‐existing autoimmune diseases treated with anti‐programmed death‐1 immunotherapy: a real‐world …
Background Patients with a history of autoimmune diseases (AIDs) have not usually been
included in clinical trials with immune checkpoint inhibitors. Materials and Methods …
included in clinical trials with immune checkpoint inhibitors. Materials and Methods …
Correlations between the immune-related adverse events spectrum and efficacy of anti-PD1 immunotherapy in NSCLC patients
Background Immune-related adverse events (irAEs) developed during immunotherapy with
anti-PD-1 agents, could be a predictive surrogate marker of clinical benefit in patients with …
anti-PD-1 agents, could be a predictive surrogate marker of clinical benefit in patients with …
[HTML][HTML] Early prediction of resistance to tyrosine kinase inhibitors by plasma monitoring of EGFR mutations in NSCLC: A new algorithm for patient selection and …
F Buttitta, L Felicioni, A Di Lorito, A Cortellini, L Irtelli… - Oncotarget, 2020 - ncbi.nlm.nih.gov
Abstract In Non-Small-Cell Lung Cancer (NSCLC) patients treated with Tyrosine Kinase-
Inhibitors (TKIs) therapy, the emergence of acquired resistance can be investigated by …
Inhibitors (TKIs) therapy, the emergence of acquired resistance can be investigated by …
Evaluating the role of FAMIly history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: the multicenter …
Background: We investigate the role of family history of cancer (FHC) and diagnosis of
metachronous and/or synchronous multiple neoplasms (MN), during anti-PD-1/PD-L1 …
metachronous and/or synchronous multiple neoplasms (MN), during anti-PD-1/PD-L1 …
The lack of head-to-head randomised trials and the consequences for patients and national health service: The case of non-small cell lung cancer
R Lasala, A Romagnoli, F Santoleri, V Isgrò… - European Journal of …, 2024 - Springer
Methods Taking into account the National Comprehensive Cancer Network (NCCN)
guidelines updated to 2022, which list all available treatments for each NSCLC subtype, the …
guidelines updated to 2022, which list all available treatments for each NSCLC subtype, the …
[HTML][HTML] Real-world outcomes of Italian patients with advanced non-squamous lung cancer treated with first-line pembrolizumab plus platinum-pemetrexed
Purpose The aim of this multi-center, retrospective/prospective cohort observational study
was to evaluate outcomes in routine clinical practice of first-line chemo-immunotherapy with …
was to evaluate outcomes in routine clinical practice of first-line chemo-immunotherapy with …
[HTML][HTML] Listening understanding and acting (lung): focus on communicational issue in thoracic oncology
CY Finocchiaro, A Rota, V Barbieri… - Translational Cancer …, 2019 - ncbi.nlm.nih.gov
Background In the field of oncological assistance, nowadays we have to deal with a complex
scenario where patients got used to obtain a huge amount of information through internet or …
scenario where patients got used to obtain a huge amount of information through internet or …
[CITATION][C] Quantification of EGFR Mutations in Plasma of NSCLC Patients: An Early Predictor of Clinical Response to Tyrosine Kinase Inhibitor
J Palma, A Marchetti, L Felicioni, T De Pas… - JOURNAL OF …, 2015 - ricerca.unich.it
Quantification of EGFR Mutations in Plasma of NSCLC Patients: An Early Predictor of Clinical
Response to Tyrosine Kinase Inhibitor IRIS IRIS Home Sfoglia Macrotipologie & tipologie …
Response to Tyrosine Kinase Inhibitor IRIS IRIS Home Sfoglia Macrotipologie & tipologie …